Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Int J Mol Sci ; 24(6)2023 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-36982856

RESUMEN

The nucleocapsid protein Np of SARS-CoV-2 is involved in the replication, transcription, and packaging of the viral genome, but it also plays a role in the modulation of the host cell innate immunity and inflammation response. Ectopic expression of Np alone was able to induce significant changes in the proteome of human cells. The cellular RNA helicase DDX1 was among the proteins whose levels were increased by Np expression. DDX1 and its related helicase DDX3X were found to physically interact with Np and to increase 2- to 4-fold its affinity for double-stranded RNA in a helicase-independent manner. Conversely, Np inhibited the RNA helicase activity of both proteins. These functional interactions among Np and DDX1 and DDX3X highlight novel possible roles played by these host RNA helicases in the viral life cycle.


Asunto(s)
COVID-19 , ARN Helicasas , Humanos , ARN Bicatenario , SARS-CoV-2 , Proteínas de la Nucleocápside , ARN Helicasas DEAD-box/genética
2.
Molecules ; 24(4)2019 Feb 22.
Artículo en Inglés | MEDLINE | ID: mdl-30813269

RESUMEN

Boron neutron capture therapy (BNCT) is a binary cancer treatment modality where two different agents (10B and thermal neutrons) have to be present to produce an effect. A dedicated trial design is necessary for early clinical trials. The concentration of 10B in tissues is an accepted surrogate to predict BNCT effects on tissues. Tissue, blood, and urines were sampled after infusion of two different boron carriers, namely BSH and BPA in the frame of the European Organisation for Research and Treatment of Cancer (EORTC) trial 11001. In this study, urine samples were used to identify protein profiles prior and after drug infusion during surgery. Here, an approach that is based on the mass spectrometry (MS)-based proteomic analysis of urine samples from head and neck squamous cell carcinoma (HNSCC) and thyroid cancer patients is presented. This method allowed the identification of several inflammation- and cancer-related proteins, which could serve as tumor biomarkers. In addition, changes in the urinary proteome during and after therapeutic interventions were detected. In particular, a reduction of three proteins that were involved in inflammation has been observed: Galectin-3 Binding Protein, CD44, and osteopontin. The present work represents a proof of principle to follow proteasome changes during complex treatments based on urine samples.


Asunto(s)
Neoplasias de Cabeza y Cuello/radioterapia , Proteómica/métodos , Carcinoma de Células Escamosas de Cabeza y Cuello/radioterapia , Neoplasias de la Tiroides/radioterapia , Adulto , Anciano , Anciano de 80 o más Años , Antígenos de Neoplasias/orina , Biomarcadores de Tumor/orina , Terapia por Captura de Neutrón de Boro/métodos , Proteínas Portadoras/orina , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de la radiación , Glicoproteínas/orina , Neoplasias de Cabeza y Cuello/metabolismo , Neoplasias de Cabeza y Cuello/orina , Humanos , Receptores de Hialuranos/metabolismo , Masculino , Persona de Mediana Edad , Osteopontina/orina , Carcinoma de Células Escamosas de Cabeza y Cuello/metabolismo , Carcinoma de Células Escamosas de Cabeza y Cuello/orina , Neoplasias de la Tiroides/metabolismo , Resultado del Tratamiento
3.
Biochem J ; 450(2): 407-15, 2013 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-23252380

RESUMEN

The halophyte Mesembryanthemum crystallinum adapts to salt stress by salt uptake and switching from C3 photosynthesis to CAM (crassulacean acid metabolism). An important role in this process is played by transport proteins in the tonoplast of the central vacuole. In the present study we examine dynamic changes in the protein composition during salt-stress adaptation in microsomes from M. crystallinum leaves. Plants challenged with 400 mM NaCl accumulate salt by day 4 of treatment and malic acid only at day 12; a switching to CAM hence follows any initial steps of salt adaptation with a delay. Using a label-free and semiquantitative approach, we identified the most dramatic changes between the proteome of control plants and plants harvested after 12 days of the treatment; the abundance of 14 proteins was significantly affected. The proteomic data revealed that the majority of the subunits of V-ATPase (vacuolar H(+)-ATPase) holoenzyme. The salt treatment somewhat decreased the abundance of all subunits in the short term (4 days). Long-term adaptation, including the switching to CAM, goes together with a strong increase in the representation of all detectable subunits. Because this increase is subunit-specific, with the highest rise occurring for subunits E and c, the data suggest that long-term adaptation to salt stress correlates with a change in V-ATPase subunit stoichiometry and highlight the structural plasticity of this holoenzyme.


Asunto(s)
Mesembryanthemum/enzimología , Hojas de la Planta/química , Proteínas de Plantas/química , ATPasas de Translocación de Protón Vacuolares/química , Mesembryanthemum/metabolismo , Fotosíntesis , Hojas de la Planta/metabolismo , Proteínas de Plantas/genética , Proteínas de Plantas/metabolismo , Proteoma/metabolismo , Proteómica , Cloruro de Sodio/metabolismo , Cloruro de Sodio/farmacología , ATPasas de Translocación de Protón Vacuolares/genética , ATPasas de Translocación de Protón Vacuolares/metabolismo , Vacuolas/enzimología , Vacuolas/metabolismo
4.
Cancer Biother Radiopharm ; 38(3): 152-159, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36269655

RESUMEN

Systems biology approach, carried out with high-throughput omics technologies, has become a fundamental aspect of the study of complex diseases like cancer. It can molecularly characterize subjects, physiopathological conditions, and interactions, allowing a precise description, to reach personalized medicine. In particular, proteomics, typically performed with liquid chromatography coupled to mass spectrometry, is a powerful tool for systems biology, giving the possibility to perform diagnosis, patient stratification, and prediction of therapy effects. Boron Neutron Capture Therapy (BNCT) is a selective antitumoral radiotherapy based on a nuclear reaction that occurs when Boron-10 (10B) atoms are irradiated by low-energy thermal neutrons, leading to cell death, thanks to the production of high-energy α particles. Since BNCT is recently becoming an important therapy for the treatment of different types of solid tumors such as gliomas, head and neck cancers, and others, it can take advantage of molecular investigation to improve the understanding of effects and mechanisms and so help its clinical applications. In this context, proteomics can provide a better understanding of mechanisms related to BNCT effect, identify potential biomarkers, and individuate differential responses by specific patients, stratifying responders and nonresponders. Another key aspect of BNCT is the study of new potential 10B carriers to improve the selectivity of Boron delivery to tumors and proteomics can be important in this application, studying the effectiveness of new boron delivery agents, including protein-based carriers, also using computational studies that can investigate new molecules, such as boronated monoclonal antibodies, for improving BNCT.


Asunto(s)
Terapia por Captura de Neutrón de Boro , Glioma , Humanos , Boro , Terapia por Captura de Neutrón de Boro/métodos , Biología de Sistemas , Glioma/tratamiento farmacológico , Compuestos de Boro/uso terapéutico
5.
Biology (Basel) ; 11(1)2022 Jan 08.
Artículo en Inglés | MEDLINE | ID: mdl-35053093

RESUMEN

Plant mitoviruses belong to Mitoviridae family and consist of positive single-stranded RNA genomes replicating exclusively in host mitochondria. We previously reported the biological characterization of a replicating plant mitovirus, designated Chenopodium quinoa mitovirus 1 (CqMV1), in some Chenopodium quinoa accessions. In this study, we analyzed the mitochondrial proteome from leaves of quinoa, infected and not infected by CqMV1. Furthermore, by protein-protein interaction and co-expression network models, we provided a system perspective of how CqMV1 affects mitochondrial functionality. We found that CqMV1 is associated with changes in mitochondrial protein expression in a mild but well-defined way. In quinoa-infected plants, we observed up-regulation of functional modules involved in amino acid catabolism, mitochondrial respiratory chain, proteolysis, folding/stress response and redox homeostasis. In this context, some proteins, including BCE2 (lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex), DELTA-OAT (ornithine aminotransferase) and GR-RBP2 (glycine-rich RNA-binding protein 2) were interesting because all up-regulated and network hubs in infected plants; together with other hubs, including CAT (catalase) and APX3 (L-ascorbate peroxidase 3), they play a role in stress response and redox homeostasis. These proteins could be related to the higher tolerance degree to drought we observed in CqMV1-infected plants. Although a specific causative link could not be established by our experimental approach at this stage, the results suggest a new mechanistic hypothesis that demands further in-depth functional studies.

6.
Cells ; 10(11)2021 11 18.
Artículo en Inglés | MEDLINE | ID: mdl-34831449

RESUMEN

Boron Neutron Capture Therapy (BNCT) is a tumor cell-selective radiotherapy based on a nuclear reaction that occurs when the isotope boron-10 (10B) is radiated by low-energy thermal neutrons or epithermal neutrons, triggering a nuclear fission response and enabling a selective administration of irradiation to cells. Hence, we need to create novel delivery agents containing 10B with high tumor selectivity, but also exhibiting low intrinsic toxicity, fast clearance from normal tissue and blood, and no pharmaceutical effects. In the past, boronated monoclonal antibodies have been proposed using large boron-containing molecules or dendrimers, but with no investigations in relation to maintaining antibody specificity and structural and functional features. This work aims at improving the potential of monoclonal antibodies applied to BNCT therapy, identifying in silico the best native residues suitable to be substituted with a boronated one, carefully evaluating the effect of boronation on the 3D structure of the monoclonal antibody and on its binding affinity. A boronated monoclonal antibody was thus generated for specific 10B delivery. In this context, we have developed a case study of Boron Delivery Antibody Identification Pipeline, which has been tested on cetuximab. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used in the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer, and head and neck cancer.


Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Terapia por Captura de Neutrón de Boro , Boro/administración & dosificación , Ácidos Borónicos/química , Simulación por Computador , Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/genética , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Mutación/genética
7.
Front Immunol ; 12: 669943, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34211466

RESUMEN

Major Histocompatibility Complex (MHC) class II (MHCII) deficiency (MHCII-D), also known as Bare Lymphocyte Syndrome (BLS), is a rare combined immunodeficiency due to mutations in genes regulating expression of MHCII molecules. MHCII deficiency results in impaired cellular and humoral immune responses, leading to severe infections and autoimmunity. Abnormal cross-talk with developing T cells due to the absence of MHCII expression likely leads to defects in thymic epithelial cells (TEC). However, the contribution of TEC alterations to the pathogenesis of this primary immunodeficiency has not been well characterized to date, in particular in regard to immune dysregulation. To this aim, we have performed an in-depth cellular and molecular characterization of TEC in this disease. We observed an overall perturbation of thymic structure and function in both MHCII-/- mice and patients. Transcriptomic and proteomic profiling of murine TEC revealed several alterations. In particular, we demonstrated that impairment of lymphostromal cross-talk in the thymus of MHCII-/- mice affects mTEC maturation and promiscuous gene expression and causes defects of central tolerance. Furthermore, we observed peripheral tolerance impairment, likely due to defective Treg cell generation and/or function and B cell tolerance breakdown. Overall, our findings reveal disease-specific TEC defects resulting in perturbation of central tolerance and limiting the potential benefits of hematopoietic stem cell transplantation in MHCII deficiency.


Asunto(s)
Células Epiteliales/inmunología , Antígenos de Histocompatibilidad Clase II/inmunología , Tolerancia Inmunológica , Inmunodeficiencia Combinada Grave/inmunología , Timo/inmunología , Adolescente , Animales , Linfocitos B/inmunología , Linfocitos B/metabolismo , Estudios de Casos y Controles , Niño , Preescolar , Modelos Animales de Enfermedad , Células Epiteliales/metabolismo , Europa (Continente) , Femenino , Trasplante de Células Madre Hematopoyéticas , Antígenos de Histocompatibilidad Clase II/genética , Antígenos de Histocompatibilidad Clase II/metabolismo , Proteínas de Homeodominio/genética , Humanos , Lactante , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , América del Norte , Proteoma , Inmunodeficiencia Combinada Grave/genética , Inmunodeficiencia Combinada Grave/metabolismo , Inmunodeficiencia Combinada Grave/cirugía , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/metabolismo , Timocitos , Timo/metabolismo , Transcriptoma , Adulto Joven
8.
Proteins ; 71(4): 1843-52, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18175312

RESUMEN

Sulfolobus solfataricus carboxypeptidase (CPSso) is a thermostable zinc-metalloenzyme, consisting of four identical subunits with a M(r) of 43,000. In a previous paper (Occhipinti et al., Biophys J 2003; 85:1165-1175), we developed a structure of the enzyme by molecular modeling and validated it by site-directed mutagenesis and small angle X-ray scattering. Here, we report investigations aimed at further validating the model, as well as at identifying molecular determinants responsible for thermostability. To this end, we took advantage of mass spectrometry techniques, notably LC-MS/MS. The structure was confirmed by such approaches, in that they lead to the identification of a disulfide bridge formed by Cys286 and Cys293, whose location in the model is well suited for giving rise to the crosslink. More notably, we also identified a protease-resistant core consisting of the N- and C-terminal antiparallel alpha-helices, which in the model are predicted to interact with each other via hydrophobic quadrants. On the basis of the model, we also tentatively identified the most tightly interacting residues as Leu7, Ala380, and Leu376. Although the replacement of Ala380 by serine did not detectably impair protein stability, a dramatic drop in thermostability was observed when the two leucines were replaced by either aspartate (L7D; L376D) or asparagine (L7N; L376N). We then investigated the kinetic thermal stability of the wild type and the mutants by determining the thermodynamic activation parameters, DeltaG++, DeltaH++, and DeltaS++. Besides highlighting the key role of the hydrophobic core in thermostability, these results suggest clearly different mechanisms of destabilization by the single mutations, depending on whether the leucines are replaced by asparagines or aspartates.


Asunto(s)
Carboxipeptidasas , Calor , Espectrometría de Masas , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Sulfolobus solfataricus/enzimología , Alquilación , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Asparagina/metabolismo , Ácido Aspártico/metabolismo , Carboxipeptidasas/análisis , Carboxipeptidasas/química , Carboxipeptidasas/genética , Cisteína/química , Disulfuros/química , Activación Enzimática/efectos de los fármacos , Estabilidad de Enzimas , Concentración de Iones de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Cinética , Modelos Químicos , Datos de Secuencia Molecular , Peso Molecular , Oxidación-Reducción , Pepsina A/farmacología , Ingeniería de Proteínas/métodos , Estructura Secundaria de Proteína , Subunidades de Proteína/química , Serina/metabolismo , Termodinámica , Tripsina/farmacología
9.
Crit Rev Oncol Hematol ; 68(1): 66-90, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18439836

RESUMEN

Boron Neutron Capture Therapy (BNCT) is based on the ability of the stable isotope 10B to capture neutrons, which leads to a nuclear reaction producing an alpha- and a 7Li-particle, both having a high biological effectiveness and a very short range in tissue, being limited to approximately one cell diameter. This opens the possibility for a highly selective cancer therapy. BNCT strongly depends on the selective uptake of 10B in tumor cells and on its distribution inside the cells. The chemical properties of boron and the need to discriminate different isotopes make the investigation of the concentration and distribution of 10B a challenging task. The most advanced techniques to measure and image boron are described, both invasive and non-invasive. The most promising approach for further investigation will be the complementary use of the different techniques to obtain the information that is mandatory for the future of this innovative treatment modality.


Asunto(s)
Terapia por Captura de Neutrón de Boro , Boro/metabolismo , Neoplasias/radioterapia , Radiobiología , Autorradiografía , Humanos , Isótopos , Imagen por Resonancia Magnética , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Neoplasias/metabolismo , Neoplasias/patología , Tomografía de Emisión de Positrones , Radiobiología/métodos , Espectrometría gamma , Espectrofotometría Atómica , Espectroscopía de Pérdida de Energía de Electrones , Distribución Tisular
10.
FEBS J ; 273(18): 4277-86, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16939621

RESUMEN

The protein ataxin-3 is responsible for spinocerebellar ataxia type 3, a neurodegenerative disease triggered when the length of a stretch of consecutive glutamines exceeds a critical threshold. Different physiologic roles have been suggested for this protein. More specifically, recent papers have shown that the highly conserved N-terminal Josephin domain of ataxin-3 binds ubiquitin and has ubiquitin hydrolase activity, thanks to a catalytic device specific to cysteine proteases. This article shows that the protein also has autoproteolytic activity, sustained by the same residues responsible for the ubiquitin hydrolase activity. The autolytic activity was abolished when these residues, i.e. Cys14 and His119, were replaced by noncatalytic ones. Furthermore, we found that pretreatment of the protein with tosyl l-phenylalanine chloromethyl ketone also abolished this activity, and that this site-specific reagent covalently bound His119, findings supported by MS experiments. MS also allowed us to establish that the attack was aspecific, as cleavage sites were observed at the carboxyl side of apolar, acidic and polar uncharged residues, clustered in the C-terminal, unstructured domain of the protein. In contrast, the Josephin domain was preserved from attack. We propose that the autolytic activity reported here may play a role in pathogenesis, as fragments carrying expanded polyglutamines are thought to be significantly more toxic than the whole protein.


Asunto(s)
Proteínas Nucleares/química , Proteínas Nucleares/metabolismo , Factores de Transcripción/química , Factores de Transcripción/metabolismo , Clorometilcetonas de Aminoácidos/farmacología , Secuencia de Aminoácidos , Animales , Ataxina-3 , Dominio Catalítico , Cromatografía Liquida , Glutamina/metabolismo , Hidrolasas/química , Espectrometría de Masas , Ratones , Datos de Secuencia Molecular , Mutagénesis , Proteínas Nucleares/genética , Inhibidores de Proteasas/farmacología , Estructura Terciaria de Proteína , Temperatura , Factores de Transcripción/genética , Ubiquitina/metabolismo
11.
Proteomics Clin Appl ; 10(4): 457-69, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27061321

RESUMEN

Neurodegenerative diseases are characterized by slow progressive loss of one or more functions of the CNS. Worldwide, the number of people affected by neurodegeneration is dramatically high and the social impact is upsetting. While being a heterogeneous group of diseases, most of these pathologies manifest similar clinical features and illness progression, thus making their diagnosis elusive. With its ability to meet the needs of neurodegenerative research, proteomics could help facilitate the diagnosis of these disorders. This strategy, recently emerged as complementary to genomics, has led in the last years to substantial achievements in deciphering molecular mechanisms and the follow-up of neurodegenerative diseases. Specifically, aim of this review is to cover the main proteomic investigations realized in the field of familial frontotemporal dementias. This disorder is less common than Alzheimer's disease and disproportionately affects younger individuals, thus representing a major psychological and economic burden for both patients and families. Although early and accurate differential diagnosis of frontotemporal dementias is crucial because of its implications for heritability, prognosis, therapeutics, and environmental management of patients, the investigative methods currently available to clinicians are incomplete. Certainly, the development of a focused therapy cannot be separated from the investigation of biochemical pathways involved in the pathogenesis.


Asunto(s)
Enfermedad de Alzheimer/diagnóstico , Demencia Frontotemporal/diagnóstico , Proteínas del Tejido Nervioso/genética , Proteómica/métodos , Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/líquido cefalorraquídeo , Enfermedad de Alzheimer/patología , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Cromatografía Liquida , Diagnóstico Diferencial , Progresión de la Enfermedad , Electroforesis en Gel Bidimensional , Lóbulo Frontal/metabolismo , Lóbulo Frontal/patología , Demencia Frontotemporal/sangre , Demencia Frontotemporal/líquido cefalorraquídeo , Demencia Frontotemporal/patología , Regulación de la Expresión Génica , Humanos , Proteínas del Tejido Nervioso/sangre , Proteínas del Tejido Nervioso/líquido cefalorraquídeo , Proteómica/instrumentación , Transducción de Señal , Espectrometría de Masas en Tándem , Lóbulo Temporal/metabolismo , Lóbulo Temporal/patología
12.
Artículo en Inglés | MEDLINE | ID: mdl-12668066

RESUMEN

Boron neutron capture therapy is a promising binary treatment for cancer. It is based on the nuclear fission that occurs when non-radioactive 10B absorbs thermal neutrons. One of the two boron compounds currently used in clinical trials for this therapy is BSH. To ensure differentiated retention in the tumour versus normal tissue prior to treatment, routine analytical methods to determine pharmacokinetics must be available. For this purpose we have developed a new, easy and time saving approach, in which the separation of boron derivatives is performed by means of capillary electrophoresis (CE). The CE method allows analyses to be performed in short times (less than 18 min), sensitively (LOD 8 pg loaded on the capillary) quantitatively (LOQ 5 microg/ml) and with a high efficiency of separation. Moreover it is simpler than HPLC and more reproducible (intra- and inter-day values were +/-1% and +/-3%, respectively), and does not require a specific column of derivatization. Mass spectrometry analysis of boron derivatives in different samples was also performed to ensure correct attribution of the CE peaks.


Asunto(s)
Compuestos de Boro/farmacocinética , Electroforesis Capilar/métodos , Compuestos de Boro/sangre , Compuestos de Boro/orina , Terapia por Captura de Neutrón de Boro , Humanos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de Masa por Ionización de Electrospray
13.
Methods Mol Biol ; 1005: 25-38, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23606246

RESUMEN

Multidimensional protein identification technology (MudPIT) is an invaluable approach to identify proteins at large-scale level. Here, we describe a procedure of investigation to functional characterize the proteomic profile of complex samples such as those from cardiac tissues. In particular, we focus on the main steps concerning sample preparation, MudPIT analysis, tandem mass spectra processing, and biomarker discovery using label-free approaches. Finally, we report a data-derived systems biology approach to identify groups of proteins of over-, under-, and normal expression.


Asunto(s)
Expresión Génica , Miocardio/metabolismo , Proteoma/química , Programas Informáticos , Algoritmos , Animales , Biomarcadores/metabolismo , Cromatografía Liquida , Bases de Datos de Proteínas , Perfilación de la Expresión Génica , Humanos , Mapas de Interacción de Proteínas , Proteolisis , Proteoma/aislamiento & purificación , Biología de Sistemas , Espectrometría de Masas en Tándem/métodos
14.
J Pharm Biomed Anal ; 51(1): 284-7, 2010 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-19735988

RESUMEN

Within the clinical trial EORTC 11001, patients were infused with (10)B-enriched borono-phenylalanine-fructose complex (BPA-fr), or borocaptate sodium (BSH) solutions, which are used as boron carriers for boron neutron capture therapy. Urine samples were periodically collected and analyzed by (10)B NMR spectroscopy. The results revealed time-dependent metabolic changes of the administered compounds. BPA-fr dissociated to the constituents BPA and fructose, and the borate group was partly cleaved from BPA. BSH was partly aggregated to a dimer form, BSSB. These observations were previously reported for cultured cells and animal models, and are confirmed here in human cancer patients.


Asunto(s)
Borohidruros/metabolismo , Compuestos de Boro/metabolismo , Terapia por Captura de Neutrón de Boro/métodos , Fenilalanina/análogos & derivados , Compuestos de Sulfhidrilo/metabolismo , Animales , Borohidruros/orina , Compuestos de Boro/química , Compuestos de Boro/orina , Carcinoma de Células Escamosas/terapia , Ensayos Clínicos como Asunto , Fructosa/química , Neoplasias de Cabeza y Cuello/terapia , Humanos , Espectroscopía de Resonancia Magnética/métodos , Fenilalanina/química , Fenilalanina/metabolismo , Fenilalanina/orina , Compuestos de Sulfhidrilo/orina , Factores de Tiempo
15.
J Chromatogr A ; 1217(33): 5328-36, 2010 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-20621298

RESUMEN

Since red blood cells (RBCs) lack nuclei and organelles, cell membrane is their main load-bearing component and, according to a dynamic interaction with the cytoskeleton compartment, plays a pivotal role in their functioning. Even if erythrocyte membranes are available in large quantities, the low abundance and the hydrophobic nature of cell membrane proteins complicate their purification and detection by conventional 2D gel-based proteomic approaches. So, in order to increase the efficiency of RBC membrane proteome identification, here we took advantage of a simple and reproducible membrane sub-fractionation method coupled to Multidimensional Protein Identification Technology (MudPIT). In addition, the adoption of a stringent RBC filtration strategy from the whole blood, permitted to remove exhaustively contaminants, such as platelets and white blood cells, and to identify a total of 275 proteins in the three RBC membrane fractions collected and analysed. Finally, by means of software for the elaboration of the great quantity of data obtained and programs for statistical analysis and protein classification, it was possible to determine the validity of the entire system workflow and to assign the proper sub-cellular localization and function for the greatest number of the identified proteins.


Asunto(s)
Membrana Eritrocítica/química , Espectrometría de Masas/métodos , Proteínas de la Membrana , Proteómica/métodos , Programas Informáticos , Humanos , Proteínas de la Membrana/química , Proteínas de la Membrana/clasificación , Proteínas de la Membrana/aislamiento & purificación , Análisis Multivariante , Reproducibilidad de los Resultados
16.
J Pharm Biomed Anal ; 50(2): 224-7, 2009 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-19473802

RESUMEN

Standardized extracts of Ginkgo biloba L. leaves are widely used in clinical practice for the symptomatic treatment of mild to moderate dementia syndromes, cerebral insufficiency and for the enhancement of cognitive function. The main active components present in G. biloba extracts are flavonol-glycosides and terpene-lactones. In recent investigations, the sesquiterpene trilactone bilobalide has been described to exert an interesting neuroprotective effect when administered systemically to experimental animals. Oral administration of terpene-lactones either as standardized extracts or purified products is characterized by a low bioavailability. While preparing phospholipidic complex of G. biloba extracts or bilobalide, plasma levels of terpenes and sesquiterpene increase. In the present study, phospholipidic complex of bilobalide (IDN 5604) has been administered orally to rats and bilobalide levels have been determined in plasma and brain by means of a validated method based on liquid chromatography coupled to atmospheric pressure chemical ionization ion trap mass spectrometry (LC/APCI-ITMS). Due to its sensitivity (about 3pmol/ml) and specificity, LC/APCI-ITMS method proved to be a very powerful tool for pharmacokinetic studies of Ginkgo terpene-lactones. The results of the present study clearly confirm the improvement of oral bioavailability of bilobalide administered as phospholipidic complex and, for the first time, demonstrate the detection of significative amounts of bilobalide in brain. This last finding agrees with the neuroprotective activity observed for bilobalide.


Asunto(s)
Encéfalo/metabolismo , Ciclopentanos/metabolismo , Furanos/metabolismo , Ginkgólidos/metabolismo , Espectrometría de Masas/métodos , Fosfolípidos/administración & dosificación , Administración Oral , Animales , Presión Atmosférica , Disponibilidad Biológica , Calibración , Ciclopentanos/administración & dosificación , Ciclopentanos/sangre , Furanos/administración & dosificación , Furanos/sangre , Ginkgólidos/administración & dosificación , Ginkgólidos/sangre , Masculino , Ratas , Estándares de Referencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA